bel Methotrexate is an FDA-approved folic acid antagonist indicated for the treatment of rheumatoid arthritis because of its high potency and efficacy in such patients; it can also be useful in patients with juvenile idiopathic arthritis. Gubner first suggested methotrexate use in rheumatoid arthritis after he performed a double blinded-placebo controlled clinical trial of methotrexate in patients having rheumatoid arthritis. Aminopterin was originally considered as the parent compound for the methotrexate was first used successfully for the treatment of childhood leukemia. Now, methotrexate is one of the major chemotherapeutic choices for various types of cancers. The medication is also safe and effective for patients with psoriasis, systemic lupus erythematosus, inflammatory bowel disease, vasculitis, and many other connective tissue diseases. However, drug safety and efficacy have not been established in patients with blood dyscrasia, and it is not recommended in pregnant women. The medication is also effective in patients with organ transplantation because of its anti-inflammatory and immunomodulatory activity. Also, methotrexate can be combined with anti-TNF agents and shown effective in the management of patients with ulcerative colitis, lymphoma (non-Hodgkin's type), carcinoma of the breast, small-cell carcinoma of the lung, epidermal tumors of the head and neck, and carcinoma of the ovary. The medication has the same effects as cyclosporin for patients with graft-versus-host disease. Methotrexate is used off-lain cases of mycosis fungoides, dermatomyositis, pityriasis rubra pilaris, eczema, sarcoidosis, Non- Hodgkin's lymphoma (advanced stage), and non-metastatic osteosarcoma.
Methotrexate has a distinct mechanism of action regarding its use in chemotherapy and immunosuppression in autoimmune diseases. In cancer, methotrexate acts as an antifolate antimetabolite. Methotrexate is taken up into the cell by carriers called the human reduced folate carriers (SLC19A1), and it forms methotrexate-polyglutamate. Both the methotrexate and the methotrexate-polyglutamate inhibit the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate into tetrahydrofolate, the active form of folic acid. Tetrahydrofolate is necessary for the synthesis of the nucleotides of both DNA and RNA. Methotrexate-polyglutamate further inhibits the de novo purine synthesis of both purine and thymidylate synthase, thereby inhibiting DNA synthesis. This mechanism is utilized in the treatment of cancer because of its cytotoxic effect.
In autoimmune diseases, different mechanisms have involvement in choosing methotrexate as a drug of choice. It inhibits enzyme AICAR transformylase, leading to hindrance in Adenosine and Guanine metabolism, Adenosine accumulation; and due to anti-inflammatory action of adenosine, leads to repression of T-cell activation, down-regulation of B-cells, increasing activated CD-95 T cells sensitivity; and repression of methyltransferase activity, inhibition of the binding of beta-1 interleukin to its cell surface receptor.
Drug interactions- As methotrexate is highly plasma protein bound, any drug which displaces methotrexate from proteins can increase its levels in the blood.
Also, if any drug has effects on the renal clearance of methotrexate, its concentration may rise.
NSAIDs, salicylates, TMP, penicillin, warfarin, valproate, proton pump inhibitors, cyclosporin, cisplatin increases the risk of MTX toxicity in the blood; aminoglycosides, neomycin, probenecid reduces the absorption of MTX.
Most significant and serious interactions are with NSAIDs and PPIs since these are very common therapeutic choices.
A pre methotrexate evaluation is necessary before initiating medical therapy with methotrexate; this evaluation involves the blood tests which include: complete blood count with differential, renal function tests include the serum creatinine, blood urea nitrogen, and urinalysis, and liver function tests include serum bilirubin, AST, ALT, serum albumin, hepatitis serology. HIV tests are also necessary, and if appropriate, the clinician should obtain a chest radiograph as well.
Methotrexate is administered orally or as injections (intramuscular, intravenous, intrathecal, or subcutaneous) injection.
Orally: Usual dosing is as a weekly "pulse," administered as a single dose or in three divided doses over 8 hourly in 24 hours every week. Folate supplementation with 1 mg per day or 5 to 7 mg once weekly should be considered for all patients to prevent bone marrow suppression. In adults, oral absorption is dependent upon the dose taken. Peak serum levels are achievable within one to two hours.
Injection: Single-dose auto-injector can deliver MTX in certain doses such as: 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, and 30 mg.
After initiation of medical therapy with methotrexate, follow up tests should include monitoring of CBC, renal function test, and liver function tests are recommended weekly for 4 weeks and then at least bi-monthly.
Even a low dose of methotrexate is not free of the side effects. Of the most common adverse effects are the Gastrointestinal manifestations such as nausea, vomiting, mucosal ulcers, loss of appetite. These are noted in most of the patients and are easily managed. The major adverse effect of methotrexate is hepatotoxicity. These side effects are similar to the deficiency of folate and can be prevented by supplementation of methotrexate with folic acid. Also, a small elevation of aminotransferases level is common, but it is uncommon to have liver steatosis, fibrosis, and cirrhosis when taking a low dose of methotrexate. Over a long duration of treatment, ultrasound scanning and liver biopsy are required to ascertain the level of liver damage. Methotrexate belongs to category X, which means it is absolutely contraindicated for use in pregnancy. Any female of reproductive age group, being prescribed this treatment must be made aware of its potential for teratogenesis, and double contraception is mandatory. With high doses, Patients may also experience mucosal ulceration. It may also be a sign of impending methotrexate toxicity. Alopecia, fatigue, fever, increased risk of infection, low white cell count, GI bleeding, pancreatitis, bone marrow suppression (aplastic anemia), malignancy (lymphoproliferative disorders), infections, interstitial pneumonitis, and renal failure are other potentially life-threatening side effects.
Methotrexate is contraindicated for use in patients with hypersensitivity reactions to this medication. Pregnant or breastfeeding women should avoid using methotrexate due to the elevated risk of teratogenicity and excretion into breast milk. Caution is necessary for using methotrexate for patients who have pre-existing blood disorders, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia. In cases of rheumatoid arthritis or psoriasis, it is contraindicated to use methotrexate in patients with chronic liver disease, liver cirrhosis, alcoholic hepatitis, or chronic alcoholism. it is also not recommended to use methotrexate in HIV/AIDS, blood dyscrasias, renal dysfunction, radiotherapy.
Patients taking methotrexate should undergo monitoring of CBC, serum creatinine, transaminases is recommended weekly for the first four weeks and then at least bimonthly. A complete list of the current medications should be revised to avoid any possible drug interactions before prescribing methotrexate. Liver function tests (monitoring serum AST, ALT, serum albumin levels), liver biopsy can also be done in cases of hepatotoxicity. Creatinine clearance requires monitoring (50 ml/min is necessary before prescribing methotrexate) to avoid possible nephrotoxicity. Monitoring for pulmonary toxicity is also required as the patients may have a dry cough, fever, dyspnoea. baseline chest radiographs recommended to detect interstitial and alveolar infiltrates, hilar adenopathy, pleural effusions, and pulmonary fibrosis. Methotrexate may also cause reactivation of tuberculosis in endemic countries, so tests to eliminate the presence of tuberculosis are required. Also, monitory for Bone marrow toxicity as myelosuppression can occur due to folate deficiency. A sudden dip in blood counts must alert to that possibility.
High-dose methotrexate (HDMTX) is the term for doses higher than 500 mg/ml. Patients may experience nausea, mucosal ulceration, alopecia, fatigue, fever, increased risk of infection, leukopenia, GI bleeding, pancreatitis, cirrhosis, aplastic anemia, malignancy (lymphoproliferative disorders), infections, interstitial pneumonitis, renal impairment, and teratogenesis. To manage MTX toxicity: immediate leucovorin administration. In the case of renal failure, adequate hydration, and urinary alkalinization with sodium bicarbonate are necessary.
The three antidotes used for MTX toxicity are leucovorin, thymidine, and glucarpidase. Leucovorin is the reduced active form of folic acid. It rescues normal cells from the toxic effects caused by MTX’s inhibition of reduced folates. Leucovorin is particularly effective in preventing myelosuppression, gastrointestinal toxicity, and neurotoxicity during methotrexate treatment. Thymidine rescues cells from the cytotoxic effects of MTX; however, its use is still under investigation and is always given together with the other drugs. Glucarpidase converts methotrexate into DAMPA and glutamate, two nontoxic metabolites, thus rapidly removing methotrexate in patients with renal dysfunction. Glucarpidase, in combination with leucovorin, is a common therapy for MTX toxicity. A single dose of glucarpidase reduces plasma methotrexate concentrations by 97% or more within 15 minutes. Hydration and urine alkalinization is also continued in patients requiring glucarpidase. Leucovorin therapy should continue for 48 hours after glucarpidase administration.
Hemodialysis and hemoperfusion can also lower MTX levels. Intrathecal overdoses require CSF drainage and exchange, steroids, and antidotes and Suspend the medications that interfere with methotrexate clearance (NSAIDs, salicylates, TMP, penicillin, warfarin, valproate, proton pump inhibitors, cyclosporin, cisplatin).
Measures to increase patient-doctor relationships and to sustain the continuity of treatment should be discussed with the patient before starting treatment with methotrexate to prevent morbidity to a greater extent and increase the life expectancy in cancer patients. The risk of potentially life-threatening side effects, hepatotoxicity, pulmonary toxicity, myelosuppression, and nephrotoxicity should be discussed with the patients.
Advise the patient to call 911 immediately if they develop any signs of infection (immunosuppression), experience coughing, wheezing, or shortness of breath (pulmonary toxicity), or notice unusual bleeding (liver or bone marrow suppression).
Inform patients that adverse reactions such as dizziness and fatigue might affect their ability to drive or operate machinery.
Inform patients of the risks of adverse effects of many-body systems, including gastrointestinal, hematologic, hepatic, infections, neurologic, pulmonary, renal, and skin.
Advise patients for close follow-up.
Advise patients to avoid alcohol, including beer, wine, and hard liquor, because of the increased risk of liver disease.
Advise patients that methotrexate can cause teratogenicity. Inform both female and male patients of reproductive age that they should practice any two forms of birth control- abstinence, oral contraceptives, or condom plus foam.
Discuss potential drug interactions, particularly salicylates and over-the-counter NSAIDs.
Warn patients about the possible development of malignancy, specifically lymphoma.
Discuss the importance of proper dosing and administration and that the recommended dose is once weekly and that improper daily use of the recommended dose has led to fatal toxicity. Make sure that patients fully understand the necessity for close follow-up and monitoring for toxicity.
If an accidental overdose occurs, an antidote is available (leucovorin rescue).
|||Braun J,Rau R, An update on methotrexate. Current opinion in rheumatology. 2009 May [PubMed PMID: 19373092]|
|||Weinblatt ME,Coblyn JS,Fox DA,Fraser PA,Holdsworth DE,Glass DN,Trentham DE, Efficacy of low-dose methotrexate in rheumatoid arthritis. The New England journal of medicine. 1985 Mar 28 [PubMed PMID: 3883172]|
|||Weinblatt ME, Methotrexate: who would have predicted its importance in rheumatoid arthritis? Arthritis research & therapy. 2018 May 30 [PubMed PMID: 29848356]|
|||Bedoui Y,Guillot X,Sélambarom J,Guiraud P,Giry C,Jaffar-Bandjee MC,Ralandison S,Gasque P, Methotrexate an Old Drug with New Tricks. International journal of molecular sciences. 2019 Oct 10 [PubMed PMID: 31658782]|
|||Chan ES,Cronstein BN, Methotrexate--how does it really work? Nature reviews. Rheumatology. 2010 Mar [PubMed PMID: 20197777]|
|||Chande N,Wang Y,MacDonald JK,McDonald JW, Methotrexate for induction of remission in ulcerative colitis. The Cochrane database of systematic reviews. 2014 Aug 27; [PubMed PMID: 25162749]|
|||Mikhaylov D,Hashim PW,Nektalova T,Goldenberg G, Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. The Journal of clinical and aesthetic dermatology. 2019 Jun; [PubMed PMID: 31360288]|
|||Singh RK,van Haandel L,Kiptoo P,Becker ML,Siahaan TJ,Funk RS, Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model. European journal of pharmacology. 2019 Jun 15; [PubMed PMID: 30951714]|
|||Tukukino C,Wallerstedt SM, Drug information centre queries and responses about drug interactions over 10 years - a descriptive analysis. Basic [PubMed PMID: 31310705]|
|||Shetty A,Cho W,Alazawi W,Syn WK, Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. The American journal of the medical sciences. 2017 Aug; [PubMed PMID: 28864376]|
|||Cheng L, Precision dosage of methotrexate in psoriasis. The British journal of dermatology. 2019 Jul 28; [PubMed PMID: 31353452]|
|||Lucas CJ,Dimmitt SB,Martin JH, Optimising Low Dose Methotrexate for Rheumatoid Arthritis - A Review. British journal of clinical pharmacology. 2019 Jul 5; [PubMed PMID: 31276602]|
|||Patel V,Wang Y,MacDonald JK,McDonald JW,Chande N, Methotrexate for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews. 2014 Aug 26; [PubMed PMID: 25157445]|
|||Bannwarth B,Labat L,Moride Y,Schaeverbeke T, Methotrexate in rheumatoid arthritis. An update. Drugs. 1994 Jan [PubMed PMID: 7510620]|
|||Gohar A, Response to 'Reply to Gohar on [PubMed PMID: 31058367]|
|||Kremer JM,Petrillo GF,Hamilton RA, Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. The Journal of rheumatology. 1995 Jan; [PubMed PMID: 7699678]|
|||Van der Beek JN,Oosterom N,Pieters R,de Jonge R,van den Heuvel-Eibrink MM,Heil SG, The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review. Critical reviews in oncology/hematology. 2019 Jul 9; [PubMed PMID: 31323533]|